novartis glp-1 receptor agonist Weight loss with medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans: Cell Reports Medicine GLP-1 Receptor Agonists as Treatments

Properties and functions of adipose tissue macrophages in obesity

Klausen MK, Thomsen M, Wortwein G, et al

From 4 mg, increase to 6 or 8 mg

On the basis of these findings, a clinical study program was started to investigate the efficacy and safety of tirzepatide in the treatment of obesity and obesity management

This suggests that GLP-1 RAs may be particularly valuable for adolescents with genetic forms of obesity who have limited response to lifestyle interventions

108 In March 2015, the FDA required a black box warning on Tanzeum due to the observed risk of thyroid C-cell tumors in animals, although it is unclear if this effect also occurs in humans